Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocolXiao-yi Tang, Hu Chen, Bin Zhang et al.|BMJ Open|2016Cited by 90
Abstract CT052: Clinical safety and efficacy study of TruUCAR™ GC027: The first-in-human, universal CAR-T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL)Xinxin Wang, Xi Zhang, Shiqi Li et al.|Cancer Research|2020Cited by 30
Role of Donor-Derived CD19.CAR-T Cells in Treating Patients That Relapsed after Allogeneic Hematopoietic Stem Cell TransplantationCheng Zhang, Xi Zhang, Lei Gao et al.|Blood|2019Cited by 3